These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 12640096)

  • 1. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.
    Mallofré C; Castillo M; Morente V; Solé M
    Mod Pathol; 2003 Mar; 16(3):187-91. PubMed ID: 12640096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia.
    Kunju LP; Lee CT; Montie J; Shah RB
    Pathol Int; 2005 May; 55(5):248-54. PubMed ID: 15871722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
    Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
    Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
    Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
    Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
    McKenney JK; Desai S; Cohen C; Amin MB
    Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
    Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
    Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
    Oliva E; Pinheiro NF; Heney NM; Kaufman DS; Shipley WU; Gurski C; Spicer B; Paner GP; Gown AM; Amin MB
    Hum Pathol; 2013 May; 44(5):860-6. PubMed ID: 23199526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67.
    Asgari M; Nabi Maybodi M; Abolhasani M
    Med J Islam Repub Iran; 2016; 30():400. PubMed ID: 27579290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium.
    Yin H; He Q; Li T; Leong AS
    Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):260-5. PubMed ID: 16932015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
    Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
    BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
    Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
    J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis.
    Jones TD; Zhang S; Lopez-Beltran A; Eble JN; Sung MT; MacLennan GT; Montironi R; Tan PH; Zheng S; Baldridge LA; Cheng L
    Am J Surg Pathol; 2007 Dec; 31(12):1861-7. PubMed ID: 18043040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunohistochemical distribution of p53 and Ki-67 in 2 cases of colorectal carcinoma occurring in ulcerative colitis].
    Maruyama K; Saigusa N; Baba S; Kino I
    Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():145-8. PubMed ID: 7611778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
    Barbisan F; Santinelli A; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M; van der Kwast T; Montironi R
    Cancer; 2008 Feb; 112(3):636-44. PubMed ID: 18072261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue.
    Feil G; Maurer S; Nagele U; Krug J; Bock C; Sievert KD; Stenzl A
    Eur Urol; 2008 May; 53(5):1066-72. PubMed ID: 17980954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.
    Yin H; Leong AS
    Am J Clin Pathol; 2004 May; 121(5):679-87. PubMed ID: 15151208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pagetoid variant of bladder urothelial carcinoma in situ A clinicopathological study of 11 cases.
    Lopez-Beltran A; Luque RJ; Moreno A; Bollito E; Carmona E; Montironi R
    Virchows Arch; 2002 Aug; 441(2):148-53. PubMed ID: 12189504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.
    Edgecombe A; Nguyen BN; Djordjevic B; Belanger EC; Mai KT
    Appl Immunohistochem Mol Morphol; 2012 May; 20(3):264-71. PubMed ID: 22498670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.